Terns Pharmaceuticals Inc. $(TERN)$ highlighted recent progress on its lead candidate TERN-701, an oral allosteric BCR-ABL inhibitor for the treatment of chronic myeloid leukemia (CML), in its latest corporate presentation. TERN-701 demonstrated a major molecular response (MMR) rate of 75% at 24 weeks in a Phase 1 study among patients with chronic phase CML at doses of 320 mg or higher. The candidate showed a favorable safety and tolerability profile, with no dose limiting toxicities or maximum tolerated dose identified and the majority of treatment emergent adverse events reported as low grade. As of December 2025, the study had enrolled more than 85 participants, including a significant proportion with prior exposure to other CML therapies. Terns reported approximately $1.0 billion in cash and cash equivalents, with a financial runway projected into 2031. Multiple clinical and regulatory milestones for TERN-701 are anticipated in 2026 and beyond. You can access the full presentation through the link below.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Terns Pharmaceuticals Inc. published the original content used to generate this news brief on January 12, 2026, and is solely responsible for the information contained therein.